Key result
Aminaphtone reduces microalbuminuria ~80% in a type 1 diabetes case.
Why the study?
Does aminaphtone reduce proteinuria in a patient with type 1 diabetes and albuminuria?
Case Report (n=1)
Does aminaphtone reduce proteinuria in a patient with type 1 diabetes and albuminuria?
Aminaphtone may be a promising pharmacological approach for reducing proteinuria and preventing diabetic nephropathy in patients with type 1 diabetes.
Answers are grounded in this paper and cite their sources.
Observed reduction in one case; hypothesis-generating for albuminuria in type 1 diabetes, requiring controlled trials before any consideration.
INTRODUCTION: Microalbuminuria in type 1 diabetes is the earliest manifestation of diabetic microangiopathy (nephropathy). To date, the pharmacological approach to microangiopathy has not been shown to be useful. By using aminaphtone to control nephrologic complications of insulin-dependent diabetes mellitus we first obtained a significant improvement in microalbuminuria confirming this new pharmacological approach for insulin-dependent diabetes mellitus organospecific complications control. CASE PRESENTATION: After being treated with standard therapy for insulin-dependent diabetes mellitus (insulin) for more than 20 years, a 49-year-old white man affected by insulin-dependent diabetes mellitus adopted the standard therapy aminaphtone for a period of 2 months.This therapy allowed a significant reduction of proteinuria from baseline evaluation that immediately increased after he stopped aminaphtone therapy. CONCLUSIONS: Aminaphtone therapy, used globally in the treatment and prevention of endothelial dysfunctions, could be an interesting option for patients with insulin-dependent diabetes mellitus with the express purpose of preventing diabetic nephropathy.
No takes yet. Share an insight, caveat, or question.
Romano et al. (2014) conducted a case report in Type 1 diabetes and albuminuria (n=1). Aminaphtone vs. Baseline was evaluated on Microalbuminuria. Aminaphtone therapy reduced microalbuminuria from 487.1 mg/L to 98.3 mg/L after 2 months in a patient with type 1 diabetes, with levels rebounding to 573.0 mg/L upon discontinuation.
Synapse has enriched 10 related papers. Consider them for comparative context: